Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Appili TherapeuticsAPLIF 3-Year EBITDA Growth Rate is 35.60% as of Mar. 2026, which is 53% above its 10-year median of 23.20. The stock has 2 warning signs investors should review. Among 1,135 Biotechnology companies, Appili Therapeutics ranks better than 73.74% on this metric.
During the past 12 months, Appili Therapeutics's average EBITDA Per Share Growth Rate was -733.30% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 35.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Appili Therapeutics was 58.70% per year. The lowest was -39.40% per year. And the median was 23.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Appili Therapeutics 3-Year EBITDA Growth Rate Related Terms
APLIF vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Appili Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Appili Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Appili Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Appili Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 35.60% mean?
Appili Therapeutics (APLIF) has a 3-Year EBITDA Growth Rate of 35.60% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Appili Therapeutics and its competitors. This is 53% above median its historical median of 23.20. According to the industry distribution chart, Appili Therapeutics ranks #298 out of 1135 companies in the Biotechnology industry, placing it in the top 26.3%.
Is Appili Therapeutics' 3-Year EBITDA Growth Rate too high?
Appili Therapeutics' current 3-Year EBITDA Growth Rate of 35.60% is 53% above median its 10-year median of 23.20. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Appili Therapeutics' value of 35.60% is 138.9% above this industry median. Based on the distribution chart, Appili Therapeutics ranks #298 out of 1135 companies in the Biotechnology industry, which is above the industry midpoint.
How does Appili Therapeutics' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Appili Therapeutics ranks #298 out of 1135 companies for 3-Year EBITDA Growth Rate. This puts Appili Therapeutics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Appili Therapeutics' value of 35.60% is 138.9% above this benchmark. While the company's 10-year median is 23.20 vs. the industry median of 14.90, Appili Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Appili Therapeutics's current 3-Year EBITDA Growth Rate of 35.60% is 138.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Appili Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Appili Therapeutics's current 3-Year EBITDA Growth Rate is 35.60%, which is 53% above median its own 10-year median of 23.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Appili Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Appili Therapeutics (APLIF) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 10% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 35.60%, which is 53% above median its 10-year median of 23.20 and 138.9% above the Biotechnology industry median of 14.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Appili Therapeutics (APLIF), the current 3-Year EBITDA Growth Rate is 35.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes programs namely ATI-1701, ATI-1801.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APLIF has been successfully added to your 
